|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
The Auto Beat
Byte of the Apple
Europe Insight
Eye on Asia
Getting In
Investing Insights
The New Entrepreneur
NEXT: Innovation Tools & Trends
On Media
Technology at Work
The Tech Beat
Traveler's Check
TECHNOLOGY
Product Reviews
Tech Stats
Hands On
AUTOS
Home Page
Auto Reviews
Car Care & Safety
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip FINANCE Investing: Europe Annual Reports Bloomberg BW50 SCOREBOARDS Hot Growth Companies: 2008 Mutual Funds Info Tech 100 B-SCHOOLS Undergrad Programs Rankings & Profiles |  |
NOVEMBER 10, 2003
Global Prices For A Global Market For decades, big pharmaceutical companies have priced their products differently around the world. Americans pay the most for the latest drugs, while those in Europe, Canada, Australia, Japan, and other advanced countries pay significantly less. The higher profits generated in the U.S. go into drug research and development, benefiting everyone. But the international price differentials, so key to the business model of giant drug companies, are being eroded by economic, political, and technological forces. Prozac, Vioxx, and other drugs sold more cheaply in Canada, Mexico, and elsewhere by U.S. companies are pouring back into American retirement communities from Florida to Arizona. Illinois may import drugs to lower its Medicaid costs. And Congress may soon allow some reimporting of drugs from Canada. It's time for Big Pharma to rethink its pricing policy. To generate the profits needed to finance new drug development, it should begin raising prices for wealthy countries outside America and lowering them inside the U.S. An ad in a Palm Beach (Fla.) newspaper for Mediplan Pharmacy in Canada shows why Big Pharma must act. It lists prices from its RxDrugsFromCanada.com Web site: 90 doses of Zoloft, 100 milligrams each, costs $142.40, vs. $232.68 in the U.S. Lipitor is offered at $172.38, vs. $311.80 in the U.S. A more integrated pricing structure for wealthy nations (with special low prices for poor countries in Africa and elsewhere) may be inevitable. Like it or not, a global market means global pricing.  Get BusinessWeek directly on your desktop with our RSS feeds.  Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2003, Bloomberg L.P.Terms of Use | Privacy Policy |
Printer-Friendly Version
